This JMCP article describes how the Biosimilars Collective Intelligence Consortium (BBCIC) has the ability to coordinate sophisticated post-approval survellience of biologics and biosimilars by utilizing its distributed research network.
Major reasons for the slow uptake of outcomes-based risk-sharing agreements in the U.S. are regulatory issues, operational requirements, and deficits in information sharing, according to a literature review published in JMCP.
AMCP CEO Blog: With PA so often misunderstood, perhaps we need to do a better job of explaining this tool to the general public. For example, we might provide an example of how PAs are applied to opioids as additional safeguards to ensure their appropriate use. Or how a PA might be applied to botulinum toxin to ensure the prescription is for medical, rather than cosmetic, purposes.
By AMCP CEO Susan A. Cantrell, RPh, CAE • 11/13/19
November 2019 News & Views: Read articles on AMCP Nexus 2019 draws record attendance; AMCP launches Champion Month in November; AMCP welcomes its latest Affiliate: AMCP Great Plains
AMCP Joins Stakeholder Letter to SAMHSA on Proposed Rule to Update 42 CFR Part 2; AMCP Seeks Input on Proposed Rule to Change Anti-Kickback Statute; CMS Issues Price Transparency Rules
for Hospital and Insurers
National Harbor, Md., Oct. 29, 2019 — AMCP Nexus 2019 will welcome nearly 2,500 managed care pharmacy professionals from across the country this week for four days of educational and networking programs focused on the “intersection of value and care.”
Genomic testing technology is rapidly evolving, but these test are costly and analytically complex. This article, published in JMCP, suggests a standardized method for the development and application of clinically relevant genomic testing.